Minerva

Minerva

BMJ 1994; 308 doi: http://dx.doi.org/10.1136/bmj.308.6939.1310 (Published 14 May 1994) Cite this as: BMJ 1994;308:1310

Monoclonal antibodies have a wide range of potential applications in the diagnosis andtreatment of infections and cancer and in organ transplantation. Mouse antibodies are of limited use owing to their antigenicity and risk of adverse reactions. A study reported in Nature (1994;368:856-9) describes mice that have been engineered to produce “human” antibodies after their own production lines of murine antibodies have been disrupted. It is expected that these antibodies would have a low risk of adverse reactions.

One in five people in Britain perceive themselves to be intolerant to certain foods, says a paper in the “Lancet” (1994;343:1127-30). But the number of people with objective evidence of food allergy is much smaller. Of 93 people complaining of food intolerance, fewer than 2% were judged to react adversely to relevant foods when compared with placebo. The rate among people who did not perceive themselves to be food intolerant was 7.7%.

One quarter of patients with metastases from a cancer have deposits in the brain (Cancer Investigation 1994;12:156-65). Patients and their doctors often see this development as a final step, but in fact as many as half of brain deposits are single and treatment is quite often possible.

Sugar is a nutritional villain, yet it has been implicated clearly in only one disease, dental …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe